{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:30:50Z","timestamp":1792783850414,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T00:00:00Z","timestamp":1482105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"ERDF","doi-asserted-by":"crossref","award":["REIPI RD12\/0015"],"award-info":[{"award-number":["REIPI RD12\/0015"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"FIS","award":["PI 13\/01282"],"award-info":[{"award-number":["PI 13\/01282"]}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.cmi.2016.12.005","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T17:01:33Z","timestamp":1481302893000},"page":"363-372","source":"Crossref","is-referenced-by-count":154,"title":["Intravenous fosfomycin\u2014back to the future. Systematic review and meta-analysis of the clinical literature"],"prefix":"10.1016","volume":"23","author":[{"given":"B.","family":"Grabein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Graninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rodr\u00edguez Ba\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.B.","family":"Liesenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2016.12.005_bib1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1749-6632.1974.tb43277.x","article-title":"The mechanism of action of fosfomycin (phosphonomycin)","volume":"235","author":"Kahan","year":"1974","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cmi.2016.12.005_bib2","unstructured":"Paul-Ehrlich-Gesellschaft f\u00fcr Chemotherapie. Resistenzstudie 2013. Abschlussbericht Teilprojekt H - Epidemiologie und Resistenzsituation bei klinisch wichtigen Infektionserregern aus dem Hospitalbereich gegen\u00fcber Antibiotika. 2015. Available at: http:\/\/www.p-e-g.org\/econtext\/Berichte%20der%20Studien\/."},{"key":"10.1016\/j.cmi.2016.12.005_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jac\/43.2.211","article-title":"In-vitro activity of fosfomycin against vancomycin-resistant enterococci","volume":"43","author":"Allerberger","year":"1999","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2016.12.005_bib4","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1128\/AAC.00721-09","article-title":"Susceptibility of urinary tract bacteria to fosfomycin","volume":"53","author":"Maraki","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2016.12.005_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum \u03b2-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.005_bib6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ijantimicag.2015.02.003","article-title":"Susceptibility of anaerobes to fusidic acid and fosfomycin","volume":"45","author":"Boyanova","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2016.12.005_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2009.03.009","article-title":"Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies","volume":"34","author":"Falagas","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2016.12.005_bib8","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/jac\/dkh158","article-title":"Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis","volume":"53","author":"Pfausler","year":"2004","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2016.12.005_bib9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/BF01647220","article-title":"Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges","volume":"15","author":"Kuhnen","year":"1987","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2016.12.005_bib10","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/jac\/dkp230","article-title":"High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection","volume":"64","author":"Schintler","year":"2009","journal-title":"J\u00a0Antimocrob Chemother"},{"key":"10.1016\/j.cmi.2016.12.005_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkq070","article-title":"Extracellular concentrations of fosfomycin in lung tissue of septic patients","volume":"65","author":"Matzi","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2016.12.005_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/AAC.47.1.371-374.2003","article-title":"Penetration of fosfomycin into inflammatory lesions in patients wich cellulitis or diabetic foot syndrome","volume":"47","author":"Legat","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2016.12.005_bib13","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1128\/AAC.01321-15","article-title":"Population pharmacokinetics of fosfomycin in critically ill patients","volume":"59","author":"Parker","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2016.12.005_bib14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/cid\/ciu580","article-title":"Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial","volume":"59","author":"del R\u00edo","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.005_bib15","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J\u00a0Stat Software"},{"key":"10.1016\/j.cmi.2016.12.005_bib16","first-page":"879","article-title":"Cellulite de la r\u00e9gion orbitaire chez l'enfant","volume":"1","author":"Aidan","year":"1994","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.cmi.2016.12.005_bib17","first-page":"746","article-title":"[Choice of first-line antibiotic therapy in the treatment of bone and joint infections in children]","volume":"36","author":"Badelon","year":"1988","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.cmi.2016.12.005_bib18","series-title":"Fosfomycin \u2013 Berichtsband zum Workshop Aktuelle Aspekte in der Infektionstherapie","first-page":"19","article-title":"Infektionen in der P\u00e4diatrischen Onkologie","author":"Bode","year":"1986"},{"issue":"6","key":"10.1016\/j.cmi.2016.12.005_bib19","article-title":"Fosfomicina sola o asociada a otros antibioticos","volume":"3","author":"Cedrato","year":"1977","journal-title":"Revissa Argentina de Pediatria"},{"issue":"3","key":"10.1016\/j.cmi.2016.12.005_bib20","article-title":"Septicemia neonatal\u2014consideracoes etiopatogenicas terapeuticas","volume":"46","author":"Chung","year":"1979","journal-title":"J\u00a0pediat (Rio de J)"},{"key":"10.1016\/j.cmi.2016.12.005_bib21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/adc.88.6.512","article-title":"Fosfomycin for the initial treatment of acute haematogenous osteomyelitis","volume":"88","author":"Corti","year":"2003","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.cmi.2016.12.005_bib22","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/BPO.0b013e3181558a9a","article-title":"Hematogenous osteomyelitis of the wrist in children","volume":"27","author":"Fitoussi","year":"2007","journal-title":"J\u00a0Pediatr Orthop"},{"key":"10.1016\/j.cmi.2016.12.005_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.arcped.2005.09.032","article-title":"Acute ethmoiditis in children, a series of 125 cases","volume":"13","author":"Fran\u00e7ois","year":"2006","journal-title":"Arch pediatr"},{"key":"10.1016\/j.cmi.2016.12.005_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0003-438X(04)95497-7","article-title":"[Suppurative cervical lymphadenitis in children. Review of 45 patients]","volume":"121","author":"Fran\u00e7ois","year":"2004","journal-title":"Ann Otolaryngol Chir Cervicofac"},{"key":"10.1016\/j.cmi.2016.12.005_bib25","first-page":"21","article-title":"Septicemies nosocomiales a staphylocoques epidermidis et aures chez le nouveaun\u00e9","volume":"37","author":"Gouyon","year":"1990","journal-title":"Ann Pediatr Paris"},{"key":"10.1016\/j.cmi.2016.12.005_bib26","first-page":"2135","article-title":"L'association fosfomycine-c\u00e9fotaxime dans les infections s\u00e9v\u00e8res staphylococciques du nouveau-n\u00e9","volume":"14","author":"Gouyon","year":"1985","journal-title":"La Presse M\u00e9d"},{"key":"10.1016\/j.cmi.2016.12.005_bib27","first-page":"21","article-title":"Resistenz der Staphylokokken gegen intrazellul\u00e4re Abt\u00f6tung durch Makrophagen \u2013 ein neuses pathophysiologisches Konzept der akuten h\u00e4matogenen Osteomyelitis im Kindesalter und seine therapeutischen Konsequenzen","volume":"24","author":"Guggenbichler","year":"1989","journal-title":"P\u00e4diatrie und P\u00e4dologie"},{"key":"10.1016\/j.cmi.2016.12.005_bib28","series-title":"Fosfomycin \u2013 ein neuartiges Antibiotikum, Internationales Symposiums Salzburg 1982","first-page":"169","article-title":"Fosfomycin in der Behandlung der eitrigen Meningitis im Fr\u00fch- und Neugeborenenalter","author":"Guggenbichler","year":"1983"},{"key":"10.1016\/j.cmi.2016.12.005_bib29","first-page":"750","article-title":"[Comparative pharmacokinetics of fosfomycin in the neonate: 2 modes of administration]","volume":"35","author":"Guibert","year":"1987","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.cmi.2016.12.005_bib30","first-page":"25","article-title":"Fosfomycin: prospektive Analyse von 100 Behandlungskursen in einem p\u00e4diatrisch onkologischen Zentrum","volume":"17","author":"Hepping","year":"2008","journal-title":"Chemother J"},{"key":"10.1016\/j.cmi.2016.12.005_bib31","first-page":"3409","article-title":"Clinical experiences of fosfomycin (FOM) for intravenous injection against severe infantile acute bacterial infections","volume":"23","author":"Hori","year":"1975","journal-title":"Chemotherapy (Jpn)"},{"key":"10.1016\/j.cmi.2016.12.005_bib32","series-title":"Fosfomycin. Berichtsband zum Workshop P\u00e4diatrie","first-page":"46","article-title":"Behandlungsm\u00f6glichkeiten bei Ventilsepsis","author":"Klumpp","year":"1985"},{"key":"10.1016\/j.cmi.2016.12.005_bib33","first-page":"457","article-title":"Exp\u00e9rience de la fosfomycine dans le traitement des infections s\u00e9v\u00e8res en r\u00e9animation p\u00e9diatrique","volume":"34","author":"Lagier","year":"1987","journal-title":"Ann P\u00e9diatr (Paris)"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2016.12.005_bib34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000222069","article-title":"Acute infantile pneumonopathies treated with fosfomycin","volume":"23","author":"Llorens","year":"1977","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2016.12.005_bib35","series-title":"Fosfomycin. Proceedings of the International Symposium. March 1986 Mexico","first-page":"229","article-title":"Fosfomycin in the treatment of infections difficult to treat","author":"Marget","year":"1987"},{"issue":"3","key":"10.1016\/j.cmi.2016.12.005_bib36","article-title":"Fosfomicina como terapeutica antiinfecciosa em pediatria","volume":"77","author":"Panico Grecco","year":"1978","journal-title":"A\u00a0Folha Medica"},{"key":"10.1016\/j.cmi.2016.12.005_bib37","series-title":"Fosfomycin - ein neuartiges Antibiotikum, Internationales Symposiums Salzburg 1982","first-page":"181","article-title":"Fosfomycin in der Behandlung der akuten h\u00e4matogenen Osteomyelitis im S\u00e4uglingsalter","author":"Pillwein","year":"1983"},{"key":"10.1016\/j.cmi.2016.12.005_bib38","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s150100070020","article-title":"Chronic osteomyelitis in childhood: is surgery always indicated?","volume":"28","author":"Reinehr","year":"2000","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2016.12.005_bib39","first-page":"172","article-title":"Behandlung von Sepsiserkrankungen im Kindesalter mit zeitlich versetzter Gabe von Antibiotika-Kombinationen","volume":"141","author":"Riedl","year":"1991","journal-title":"Wien Medizin Wochenschr"},{"key":"10.1016\/j.cmi.2016.12.005_bib40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0399-077X(83)80023-7","article-title":"Infections a cocci Gram positif au cours des d\u00e9rivations de L.C.R. Traitment par l'association Fosfomycine-Oxacilline","volume":"13","author":"Roche","year":"1983","journal-title":"Med Maladies Infect"},{"key":"10.1016\/j.cmi.2016.12.005_bib41","first-page":"437","article-title":"La fosfomycine dans les infections s\u00e9v\u00e8res en n\u00e8onatologie","volume":"31","author":"Rossignol","year":"1984","journal-title":"Ann P\u00e9diat (Paris)"},{"key":"10.1016\/j.cmi.2016.12.005_bib42","first-page":"3406","article-title":"[Clinical experience with fosfomycin for intravenous use in respiratory infections]","volume":"23","author":"Sawada","year":"1975","journal-title":"Chemotherapy (Jpn)"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2016.12.005_bib43","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000222084","article-title":"Antibiotherapy of Serratia marcescens septicemia in children","volume":"23","author":"Baquero","year":"1977","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2016.12.005_bib44","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/00365548.2011.616221","article-title":"Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria","volume":"44","author":"Dinh","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.005_bib45","first-page":"525","article-title":"Traitement des ventriculites a Staphylococcus epidermidis sur materiel par l'association fosfomycine-aminoside. Evolution des taux ventriculaires de fosfomycine","volume":"31","author":"Boulard","year":"1983","journal-title":"Pathol Biol Paris"},{"key":"10.1016\/j.cmi.2016.12.005_bib46","first-page":"3556","article-title":"Exp\u00e9rience de la fosfomycine dans le traitement des septic\u00e9mies \u00e0 staphylocoque","volume":"63","author":"Dureux","year":"1987","journal-title":"Sem Hop Paris"},{"key":"10.1016\/j.cmi.2016.12.005_bib47","first-page":"191","article-title":"Interet de la fosfomycine en association dans le traitement des infections graves","volume":"244","author":"Fleurette","year":"1980","journal-title":"Lyon Med"},{"key":"10.1016\/j.cmi.2016.12.005_bib48","series-title":"Current Chemotherapy. Proceedings of the 10th International Congress on Chemotherapy","first-page":"677","article-title":"Five years' experience with fosfomycin in a Spanish hospital. Bacteriological and clinical results","author":"Gobernado","year":"1978"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2016.12.005_bib49","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000222082","article-title":"Fosfomycin in a traumatological department","volume":"23","author":"Hernandesz-Casado","year":"1977","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2016.12.005_bib50","first-page":"3686","article-title":"[Basic and clinical studies on fosfomycin in orthopedic field]","volume":"23","author":"Itami","year":"1975","journal-title":"Chemotherapy (Jpn)"},{"key":"10.1016\/j.cmi.2016.12.005_bib51","first-page":"839","article-title":"[Treatment of post-traumatic and post-neurosurgical bacterial meningitis with ceftriaxone alone or in combination with fosfomycin]","volume":"35","author":"May","year":"1987","journal-title":"Pathol Biol (Paris)"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2016.12.005_bib52","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000222083","article-title":"Evaluation of Fosfomycin in an Intensive Care Unit","volume":"23","author":"Pardo Zubiris","year":"1977","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2016.12.005_bib53","first-page":"1","article-title":"Infecciones diversas tratadas con fosfomicina","volume":"27","author":"Perea","year":"1974","journal-title":"Progr terap\u00e9ut cl\u00edn"},{"issue":"Suppl B","key":"10.1016\/j.cmi.2016.12.005_bib54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/jac\/14.suppl_B.277","article-title":"Treatment of severe staphylococcal infections with cefotaxime and fosfomycin in combination","volume":"14","author":"Portier","year":"1984","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.cmi.2016.12.005_bib55","first-page":"84","article-title":"Fosfomicina en meningitis neumococica","volume":"2","author":"Ruiz Moyano","year":"1981","journal-title":"Inmunologika"},{"key":"10.1016\/j.cmi.2016.12.005_bib56","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000238009","article-title":"Fosfomycin penetration into the cerebrospinal fluid of patients with bacterial meningitis","volume":"27","author":"Sicilia","year":"1981","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2016.12.005_bib57","first-page":"436","article-title":"[Fosfomycin \u2013 a new antibiotic in rhinootolaryngology]","volume":"31","author":"Stammberger","year":"1983","journal-title":"HNO"},{"key":"10.1016\/j.cmi.2016.12.005_bib58","first-page":"3525","article-title":"Therapeutic experience of intravenous fosfomycin (Fom-Na) in orthopedical field","volume":"23","author":"Yano","year":"1975","journal-title":"Chemotherapy (Jpn)"},{"key":"10.1016\/j.cmi.2016.12.005_bib59","first-page":"514","article-title":"[A combined consecutive therapy with fosfomycin and sulbactam\/cefoperazone for bacterial infections associated with hematological diseases]","volume":"48","author":"Misawa","year":"1995","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.cmi.2016.12.005_bib60","first-page":"171","article-title":"[Clinical evaluation of imipenem\/cilastatin sodium and fosfomycin as second-line combination chemotherapy in severe infections associated with hematologic disorders]","volume":"46","author":"Tsuda","year":"1993","journal-title":"Jpn J Antibiot"},{"issue":"Suppl.\u00a0Pt 1","key":"10.1016\/j.cmi.2016.12.005_bib61","article-title":"[Combination effect of fosfomycin and sulbactam\/cefoperazone for opportunistic infections in patients with hematological disorders: a randomised crossover trial of sequential administration]","volume":"88","author":"Hiraoka","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2016.12.005_bib62","doi-asserted-by":"crossref","first-page":"761","DOI":"10.11150\/kansenshogakuzasshi1970.72.761","article-title":"[Clinical efficacy of fosfomycin in combination with sulbactam\/cefoperazone in the treatment of severe infections complicated to blood dyscrasia. Working Group of Kanto Combination Therapy for FOM\u00a0+ SBT\/CPZ]","volume":"72","author":"Kitamura","year":"1998","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.cmi.2016.12.005_bib63","first-page":"521","article-title":"[Clinical effects of a combination treatment with fosfomycin and clavulanic acid\/ticarcillin for infections in patients complicated with hematological disorders]","volume":"47","author":"Hirakawa","year":"1994","journal-title":"Jpn J Antibiot"},{"issue":"1","key":"10.1016\/j.cmi.2016.12.005_bib64","article-title":"[Comparative study of the efficacy on fosfomycin Na and sulbenicilin Na against the chronic urinary tract infections by Pseudomonas aeruginosa and Proteus vulgaris]","volume":"25","author":"Sano","year":"1979","journal-title":"Acta Urol Jpn"},{"key":"10.1016\/j.cmi.2016.12.005_bib65","first-page":"429","article-title":"Clinical analysis of combined consecutive therapy with fosfomycin and sulbactam\/cefoperazone for patients with pneumonia","volume":"50","author":"Kobashi","year":"2002","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.cmi.2016.12.005_bib66","first-page":"1261","article-title":"[Effects of cefotaxime single administration and of cefotaxime\u00a0+ fosfomycin administration against respiratory tract infections]","volume":"41","author":"Shimokata","year":"1988","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.cmi.2016.12.005_bib67","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2016.12.005_bib68","first-page":"96","article-title":"Fosfomycin versus ampicillin in the treatment of acute pyelonephritis","volume":"7","author":"Ode","year":"1988","journal-title":"Chemioterapia"},{"key":"10.1016\/j.cmi.2016.12.005_bib69","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/BF01644272","article-title":"Fosfomycin-ampicillin versus gentamicin-ampicillin in the treatment of critically ill patients with pneumonia","volume":"14","author":"Nissen","year":"1986","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2016.12.005_bib70","first-page":"361","article-title":"[Observations on the effect of sodium fosfomycin on the lower respiratory tract infection]","volume":"28","author":"Zhang","year":"2003","journal-title":"Chin J Antibiotics"},{"key":"10.1016\/j.cmi.2016.12.005_bib71","first-page":"781","article-title":"[Efficacy of combination therapy against MRSA in Ibaraki Prefecture]","volume":"47","author":"Otsuka","year":"1994","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.cmi.2016.12.005_bib72","first-page":"428","article-title":"Note cliniche sull'impiego della fosfomicina in ostetricia e ginecologia","volume":"117","author":"Albano","year":"1978","journal-title":"Boil Chim Farm"},{"key":"10.1016\/j.cmi.2016.12.005_bib73","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0248-8663(87)80116-9","article-title":"Comparaison entre fosfomycine-p\u00e9nicilline M et p\u00e9nicilline M-Gentamicine. A propos de 35 infections s\u00e9v\u00e8res \u00e0 Staphylococcus aureus m\u00e9ticilline-sensibles","volume":"8","author":"Baron","year":"1987","journal-title":"Rev M\u00e9d interne"},{"key":"10.1016\/j.cmi.2016.12.005_bib74","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ijantimicag.2011.11.012","article-title":"Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin","volume":"39","author":"Apisarnthanarak","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2016.12.005_bib75","first-page":"819","article-title":"Combination chemotherapy for infections due to methicillin-resistant Staphylococcus aureus with combination therapy by cefuzonam and fosfomycin or minocycline in the urologic field","volume":"15","author":"Matsumoto","year":"1993","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2016.12.005_bib76","series-title":"Fosfomycin. Proceedings of the International Symposium. March 1986 Mexico","first-page":"136","article-title":"Fosfomycin in the treatment of osteomyelitis","author":"Guerrero","year":"1987"},{"key":"10.1016\/j.cmi.2016.12.005_bib77","series-title":"Fosfomycin. Proceedings of the International Symposium. March 1986 Mexico","first-page":"172","article-title":"Clinical Study on combined therapy with fosfomycin for staphylococcal infections","author":"Baron","year":"1987"},{"key":"10.1016\/j.cmi.2016.12.005_bib78","series-title":"Septicemias e infecciones \u00f3seas por Staphylococcus aureus resistentes a la meticilina y a los aminogluc\u00f3sidos. Tratamiento con fosfomicina-oxacilina. Inmunologika","first-page":"80","author":"Baron","year":"1981"},{"key":"10.1016\/j.cmi.2016.12.005_bib79","series-title":"Probl\u00e8mes actuels de pathologie infectieuse et de r\u00e9animation","first-page":"1","article-title":"Les infections a staphylocoques meticilline-resistants","author":"Baron","year":"1984"},{"key":"10.1016\/j.cmi.2016.12.005_bib80","first-page":"798","article-title":"Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections","volume":"47","author":"Kono","year":"1994","journal-title":"Jpn J Antibiotics"},{"key":"10.1016\/j.cmi.2016.12.005_bib81","first-page":"419","article-title":"In\u00a0vitro and in\u00a0vivo study of fosfomycin in methicillin-resistant Staphylococcus aureus septicaemia","volume":"96","author":"Lau","year":"1986","journal-title":"J\u00a0Hyg Camb"},{"key":"10.1016\/j.cmi.2016.12.005_bib82","first-page":"909","article-title":"[Severe infections caused by methicillin-resistant Staphylococcus aureus. 62 cases]","volume":"22","author":"May","year":"1993","journal-title":"Presse Med"},{"key":"10.1016\/j.cmi.2016.12.005_bib83","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1086\/657249","article-title":"Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia","volume":"51","author":"Apisarnthanarak","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.005_bib84","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1469-0691.2009.02921.x","article-title":"Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation","volume":"16","author":"Michalopoulos","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2016.12.005_bib85","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2013.09.010","article-title":"Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria","volume":"43","author":"Pontikis","year":"2014","journal-title":"International J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2016.12.005_bib86","first-page":"11","article-title":"Antimikrobielle Therapie der Spondylodiszitis \u2013 \u00dcberlegungen zur Optimierung","volume":"14","author":"St\u00f6ckl","year":"2005","journal-title":"Chemother J"},{"key":"10.1016\/j.cmi.2016.12.005_bib87","first-page":"527","article-title":"Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin","volume":"17","author":"Stengel","year":"2005","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2016.12.005_bib88","series-title":"Klinische Pr\u00fcfung BM 04.005 (Fosfomycin). Abschlussbericht f\u00fcr die 4-Gramm-Tagesdosis. Klinische Entwicklung Abteilung Chemotherapie","author":"Timmler","year":"1978"},{"key":"10.1016\/j.cmi.2016.12.005_bib89","series-title":"Klinische Pr\u00fcfung BM 04.005 (Fosfomycin). Abschlussbericht f\u00fcr die 6-Gramm-Tagesdosis. Klinische Entwicklung Abteilung Chemotherapie","author":"Timmler","year":"1978"},{"key":"10.1016\/j.cmi.2016.12.005_bib90","series-title":"Proceedings of the 13th International Congress of Chemotherapy","first-page":"8","article-title":"Ventricular fluid concentration of fosfomycin in patients with ventriculitis","author":"Quentin","year":"1983"},{"key":"10.1016\/j.cmi.2016.12.005_bib91","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/BF01644014","article-title":"Adjuvant fosfomycin medication in chronic osteomyelitis","volume":"17","author":"Meissner","year":"1989","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2016.12.005_bib92","first-page":"3300","article-title":"Keimelimination durch Fosfomycin bei komplizierten Harnwegsinfektionen","volume":"33","author":"Naber","year":"1983","journal-title":"Therapiewoche"},{"key":"10.1016\/j.cmi.2016.12.005_bib93","series-title":"Fosfomycin. Proceedings of the International Symposium. March 1986 Mexico","first-page":"166","article-title":"Fosfomycin in the treatment of septicemia","author":"Gudin","year":"1987"},{"key":"10.1016\/j.cmi.2016.12.005_bib94","first-page":"177","article-title":"Traitement par la fosfomycine des infections severes observees en service de reanimation","volume":"243","author":"Bertoye","year":"1980","journal-title":"Lyon Med"},{"key":"10.1016\/j.cmi.2016.12.005_bib95","first-page":"4372","article-title":"Wirksamkeit, Nebenwirkungen und Pharmakokinetik von Fosfomycin bei Hals-Nasen-Ohren-Infektionen","volume":"33","author":"Federspil","year":"1983","journal-title":"Therapiewoche"},{"key":"10.1016\/j.cmi.2016.12.005_bib96","first-page":"748","article-title":"Klinische Erfahrungen mit Fosfomycin bei Harnwegsinfektionen","volume":"123","author":"Peters","year":"1981","journal-title":"MMW Munch Med Wochenschr"},{"key":"10.1016\/j.cmi.2016.12.005_bib97","first-page":"168","article-title":"Fosfomycin, klinische Wirksamkeit und Vertr\u00e4glichkeit bei Harnwegsinfektionen","volume":"11","author":"Peters","year":"1982","journal-title":"Klinikarzt"},{"key":"10.1016\/j.cmi.2016.12.005_bib98","first-page":"890","article-title":"In\u00a0vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases","volume":"42","author":"Santimaleeworagun","year":"2011","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.cmi.2016.12.005_bib99","series-title":"Breakpoint tables for interpretation of MICs and zone diameters","author":"The European Committee on Antimicrobial Susceptibility Testing","year":"2016"},{"key":"10.1016\/j.cmi.2016.12.005_bib100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/BF02017607","article-title":"Development of resistance during antibiotic therapy","volume":"6","author":"Milatovic","year":"1987","journal-title":"Eur J Clin Microbiol"},{"key":"10.1016\/j.cmi.2016.12.005_bib101","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/j.1875-9114.1995.tb04366.x","article-title":"Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies","volume":"15","author":"Fish","year":"1995","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2016.12.005_bib102","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jac\/dkr466","article-title":"Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens","volume":"67","author":"Karageorgopoulos","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2016.12.005_bib103","doi-asserted-by":"crossref","first-page":"e007363","DOI":"10.1136\/bmjopen-2014-007363","article-title":"Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial","volume":"5","author":"Rosso-Fern\u00e1ndez","year":"2015","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.cmi.2016.12.005_bib104","doi-asserted-by":"crossref","first-page":"e006723","DOI":"10.1136\/bmjopen-2014-006723","article-title":"Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial","volume":"5","author":"Shaw","year":"2015","journal-title":"BMJ Open"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16306103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16306103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T23:24:17Z","timestamp":1718925857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X16306103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":104,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1198743X16306103"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2016.12.005","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727104298.793549923","asserted-by":"object"}]},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}